A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.

Primary tabs

field_vote: 
No votes yet
Publication type: 
Number of included patients: 
References: 
Disease(s): 

A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.

 

 


2008 ASCO Annual Meeting

 
Abstract No:

519

 
Citation:

J Clin Oncol 26: 2008 (May 20 suppl; abstr 519)

 
Author(s):

E. L. Mayer, K. D. Miller, H. S. Rugo, J. M. Peppercorn, L. A. Carey,
N. Ryabin, K. Josephs, E. P. Winer, H. J. Burstein
Abstract:

Background:
Patients (pts) with residual breast cancer after neoadjuvant
chemotherapy are at increased risk of recurrence, and may have
chemotherapy-resistant disease. We sought to explore adjuvant
antiangiogenic therapy combined with two different chemotherapy
regimens in this population.
Methods: Eligible pts had stage
II-III breast cancer with residual invasive carcinoma at surgery
following anthracycline-containing neoadjuvant chemotherapy. Treatment
consisted of bevacizumab (B) 15 mg/kg every three weeks (1 cycle) for
one year, starting no less than 1 month after surgery or 2 weeks after
radiation. Sequential cohorts also received concurrent chemotherapy,
either metronomic chemotherapy (CM): cyclophosphamide 50 mg PO qd, and
methotrexate 2.5 mg PO d 1-2 each week for a total of 6 months, or
capecitabine (X) 2,000 mg/m2/day 14d on/7d off for 18 weeks. Concurrent
endocrine and/or trastuzumab therapy was allowed. The primary endpoint
was feasibility and tolerability of the combination therapy. Results:
81 pts were treated with B + CM or B + X. Median age was 48y, 59% were
stage III, 62% were hormone receptor positive, and 11% were HER2+. To
date, the median number of cycles completed is 10 of a planned 17, with
12 pts completing treatment and 2 pts choosing to end treatment early.
At a median on-study follow-up of 7.5 months, 6 pts (7%) have had tumor
recurrence. Treatment-related toxicities include fatigue (41%),
headache (32%), arthralgias (31%), and hypertension (23%). Preliminary
analysis suggests B + CM has a more favorable side effect profile, as B
+ X led to more diarrhea, hand-foot syndrome, and grade 3/4 toxicity. 9
patients came off study for toxicity, including one patient with heart
failure. Definitive feasibility/safety data and preliminary correlative
studies will be available by June 2008. Conclusions: Adjuvant B
+ chemotherapy after neoadjuvant chemotherapy appears tolerable and
feasible with side effects including fatigue, headache, arthralgias,
and hypertension. The addition of X appears to contribute more
toxicity. As previously demonstrated in our study of B monotherapy
(Mayer et al, ASCO 2007, #561), the post- preoperative chemotherapy
population remains high risk and merits novel therapies